









Markets
/
Stocks
/
nasdaq-cmpx
/

Compass Therapeutics Inc.

CMPX

6.520USD

+0.300+4.82%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.16BMarket Cap

LossP/E TTM



Compass Therapeutics Inc.

6.520

+0.300+4.82%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Compass Therapeutics Inc.

Currency: USD Updated: 2026-02-06

Key Insights

Compass Therapeutics Inc.'s fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.46.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Compass Therapeutics Inc.'s Score

Industry at a Glance

Industry Ranking

47 / 392

Overall Ranking

154 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Compass Therapeutics Inc. Highlights

StrengthsRisks

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.

Growing

The company is in a growing phase, with the latest annual income totaling USD 850.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 850.00K.

Undervalued

The company’s latest PE is -14.46, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 147.60M shares, increasing 2.64% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 8.05M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.86.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

13.462

Target Price

+116.42%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Compass Therapeutics Inc. is 6.34, ranking 263 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.34

Change



Financials

8.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.45

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.04

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Compass Therapeutics Inc.'s Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Compass Therapeutics Inc. is 6.43, ranking 281 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -14.46, which is -84.52% below the recent high of -2.24 and -1.65% above the recent low of -14.70.

Score

Industry at a Glance

Previous score

6.43

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Compass Therapeutics Inc. is 8.93, ranking 37 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 30.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.93

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

13.462

Target Price

+116.42%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Compass Therapeutics Inc.

CMPX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Compass Therapeutics Inc. is 9.36, ranking 13 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.24 and the support level at 5.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.07

Change

0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.011

Buy

RSI(14)

62.082

Neutral

STOCH(KDJ)(9,3,3)

55.289

Neutral

ATR(14)

0.411

High Vlolatility

CCI(14)

87.493

Neutral

Williams %R

26.087

Buy

TRIX(12,20)

0.848

Sell

StochRSI(14)

67.972

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

6.402

Buy

MA10

6.355

Buy

MA20

6.050

Buy

MA50

5.561

Buy

MA100

4.813

Buy

MA200

3.732

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Compass Therapeutics Inc. is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 70.29%, representing a quarter-over-quarter decrease of 2.02%. The largest institutional shareholder is The Vanguard, holding a total of 8.05M shares, representing 4.53% of shares outstanding, with 29.34% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tang Capital Management, LLC

16.81M

+24.57%

OrbiMed Advisors, LLC

15.22M

Suvretta Capital Management, LLC

14.10M

Vivo Capital, LLC

9.55M

+57.95%

Blackstone Alternative Asset Management, L.P.

9.03M

+5.97%

BVF Partners L.P.

8.75M

+84.21%

The Vanguard Group, Inc.

Star Investors

7.06M

+45.62%

Enavate Sciences GP, LLC

7.79M

BlackRock Institutional Trust Company, N.A.

6.76M

+16.07%

Schuetz (Thomas J.)

5.56M

-0.79%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Compass Therapeutics Inc. is 4.76, ranking 71 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.28. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Compass Therapeutics Inc.’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.